Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

Complete title: A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Research Study Number 20161101
 
Principal Investigator Christina Baik
 
Phase I/II

Research Study Description

Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20161101
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Bile Duct Cancer; Brain Cancer; Breast Cancer; Glioma; Head and Neck Cancer; Lung Cancer; Melanoma; Salivary Gland Cancer; Sarcoma; Solid Tumors; Thyroid Cancer; Neoplasms, Germ Cell and Embryonal; Lung Carcinoma, Non-Small-Cell (NSCLC); Carcinoma, Bronchogenic; Glioblastoma; Astrocytoma; Carcinoma, Squamous Cell; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Colorectal Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Ductal; Neoplasms, Respiratory Tract; Neoplasms, Thoracic; Biliary Tract Neoplasms; Pontine Glioma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials